NCT02377583

Brief Summary

The general objective is to precise the role of HPA axis activity in neuropsychological consequences of type 1 diabetes. The investigators hypothesize that hyperactivity of HPA axis is associated with higher scores of depression and changes in hippocampal volume and mean diffusion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2012

Typical duration for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2012

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

February 25, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 3, 2015

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

June 18, 2026

Status Verified

September 1, 2015

Enrollment Period

3.1 years

First QC Date

February 25, 2015

Last Update Submit

June 16, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Mean of nocturnal urinary free cortisol during 5 days.

    During 5 days after the inclusion

  • Depression (CDI) score

    At the inclusion

Secondary Outcomes (5)

  • Mean of awakening salivary cortisol and mean of nocturnal urinary cortisol metabolites during 5 days

    During 5 days after the inclusion

  • Profiles of glucocorticoid sensitive genes expressed in peripheral blood mononuclear cells.

    At the inclusion

  • Anxiety (STAI) score

    At the inclusion

  • Polymorphisms of genes involved in HPA axis activity

    At the inclusion

  • Hippocampal volume and mean diffusion

    At the inclusion

Study Arms (2)

Diabetic children

EXPERIMENTAL

* physical examination * Glucocorticoid sensitivity index * DNA sample * Anxiety and depression questionnaires * depression questionnaire * MRI

Biological: T1DM analyses

Controls

NO INTERVENTION

* physical examination * Glucocorticoid sensitivity index * DNA sample * Anxiety and depression questionnaires * depression questionnaire * MRI * Laboratory tests

Interventions

T1DM analysesBIOLOGICAL
Diabetic children

Eligibility Criteria

Age6 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Diabetic group:
  • diabetes for 1 year
  • year's old
  • included in ISIS-DIAB protocol.
  • Control group:
  • brother or sister of a diabetic children
  • year's old.

You may not qualify if:

  • Other chronic disease than diabetes type1.
  • Psychiatric disorders or psychiatric treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Service d'endocrinologie pédiatrique CHG Bayonne Centre Hospitalier de la Côte Basque

Bayonne, Aquitaine, 64000, France

Location

CHU de Bordeaux Hôpital Pellegrin

Bordeaux, Aquitaine, 33000, France

Location

Service d'endocrinologie pédiatrique - Hôpital de la mère et de l'enfant - CHU de LIMOGES

Limoges, Limousin, 87000, France

Location

Related Publications (1)

  • Brossaud J, Corcuff JB, Vautier V, Bergeron A, Valade A, Lienhardt A, Moisan MP, Barat P. Altered Cortisol Metabolism Increases Nocturnal Cortisol Bioavailability in Prepubertal Children With Type 1 Diabetes Mellitus. Front Endocrinol (Lausanne). 2021 Dec 14;12:742669. doi: 10.3389/fendo.2021.742669. eCollection 2021.

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Paul PEREZ, Doctor

    University Hospital, Bordeaux

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 25, 2015

First Posted

March 3, 2015

Study Start

August 1, 2012

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

June 18, 2026

Record last verified: 2015-09

Locations